Natera (NTRA) Projected to Post Earnings on Thursday

Natera (NASDAQ:NTRA) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.59) per share and revenue of $446.68 million for the quarter. Natera has set its FY 2025 guidance at EPS.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. On average, analysts expect Natera to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Natera Stock Up 0.5 %

Natera stock opened at $157.38 on Tuesday. The firm has a market capitalization of $21.28 billion, a P/E ratio of -89.42 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera has a twelve month low of $92.14 and a twelve month high of $183.00. The stock’s fifty day simple moving average is $146.87 and its 200-day simple moving average is $154.84.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on NTRA shares. The Goldman Sachs Group increased their price target on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, March 19th. Piper Sandler increased their price objective on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research report on Friday, February 28th. Finally, Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average price target of $175.76.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the transaction, the chief executive officer now directly owns 203,354 shares in the company, valued at approximately $29,160,963.60. This trade represents a 30.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,562 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the transaction, the chief financial officer now directly owns 75,557 shares in the company, valued at approximately $10,457,844.37. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 153,099 shares of company stock worth $22,136,941. Insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.